Last reviewed · How we verify

NCT04351451

Hypomagnesemia and Hypocalcemia Association Following Thyroidectomy

Completed Last updated 17 April 2020
What this trial tests

trial testing thyroidectomy in Hypomagnesemia in 74 participants. Completed in 1 February 2020.

Timeline
1 January 2019
Primary endpoint
1 January 2020
1 February 2020

Quick facts

Lead sponsorKing Saud University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment74
Start date1 January 2019
Primary completion1 January 2020
Estimated completion1 February 2020
Sites1 location across Saudi Arabia

Drugs / interventions tested

Conditions studied

Sponsor

King Saud University

Who can join

12 and older, any sex, with Hypomagnesemia or Hypocalcemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Magnesium plays a role in the active transport of calcium (Ca+2) and potassium ions across cell membranes. Most of it is intracellular or in the bone , however less than 1% of magnesium is in the blood serum. Hypoparathyroidism post thyroidectomy leads to acute Hypocalcemia that leads to hypomagnesemia. The relation of Ca+2 and magnesium (Mg+2) metabolism is complex and mainly related to the interaction of these cations with parathyroid post thyroidectomy. (Mg+2) is an essential regulator of Ca+2 flux and intracellular action of Ca+2. Hypomagnesaemia impairs hypocalcaemia induced PTH release, which is corrected rapidly after magnesium replacement. Attempting to correct only hypocalcemia may prolong symptoms. It is important to monitor both Ca+2 \& Mg+2 levels following thyroidectomy to facilitate prompt resolution of symptoms. Aim of the study: is to highlight the prevalence of hypomagnesemia following thyroidectomy and its association with hypocalcemia which mandate early recognition and treatment to prevent prolongation of hypocalcemia and permanent hypoparathyroidism Methods: IRB obtained (E20-4615) informed consent taken from all patient. This is prospective open Label observational study in patients underwent thyroidectomy .the study period was from January 2019 to January 2020. Total of 74 patients with normal renal function. Corrected serum Ca+2, magnesium, phosphate level and vitamin D level are all checked pre operatively and in the first post-operative day. Result: Post thyroidectomy 56.8% of patients had hypomagnesemia. 59.5.1% patients had hypocalcemia and 41.9% of patients had low both Ca+2 and Mg+2 (P=0.004) Conclusion: Hypocalcemia and hypomagnesemia following thyroidectomy is of multi factorial related mainly to Ca+2, Mg+2 interaction. Keywords: Hypomagnesemia. Hypocalcemia. Thyroidectomy

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of thyroidectomy

Trials testing the same drug.

Other recruiting trials for Hypomagnesemia

Currently open trials in the same condition.

Other King Saud University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04351451.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing